Headache

Migraine Treatment

Migraine Treatment · G43

Migraine treatment consists of acute therapy to relieve ongoing attacks and preventive therapy to reduce attack frequency, with treatment strategies tailored to individual attack patterns and severity.

2026-03-26

At a Glance

Acute migraine treatment includes NSAIDs, triptans, and the newer gepants and ditans. Triptans are most effective when taken early in the attack. Overuse of acute medications (>10-15 days/month) leads to medication overuse headache. Preventive therapy is indicated when attacks occur 4+ days/month. Options include beta-blockers, topiramate, amitriptyline, and CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab). OnabotulinumtoxinA is FDA-approved for chronic migraine. Neuromodulation devices (sTMS, nVNS, eTNS) offer non-pharmacological alternatives. Lifestyle modifications including regular sleep, exercise, and trigger management are fundamental.

Definition and Overview

Migraine treatment is divided into acute therapy (aborting an ongoing attack) and preventive therapy (reducing attack frequency and severity). Treatment strategies are tailored to individual attack patterns, severity, frequency, and comorbidities [1].

Acute Treatment

Simple Analgesics and NSAIDs

Aspirin (1000 mg), ibuprofen (400-600 mg), and naproxen (500-750 mg) are effective for mild-to-moderate attacks. Early treatment at pain onset improves efficacy. Acetaminophen (1000 mg) is a second-line option [2].

Triptans

Triptans (sumatriptan, rizatriptan, zolmitriptan, eletriptan) are 5-HT1B/1D agonists and the gold standard for moderate-to-severe migraine. Most effective when taken early in the attack while pain is still mild. Approximately 60-70% of patients respond to oral triptans [3]. Contraindicated in uncontrolled hypertension, coronary artery disease, and cerebrovascular disease.

Gepants and Ditans

CGRP receptor antagonists (ubrogepant, rimegepant) and 5-HT1F agonists (lasmiditan) offer alternatives without vasoconstrictive effects, suitable for patients with cardiovascular contraindications to triptans [4].

Preventive Treatment

Indicated when attacks occur 4 or more days per month, attacks are severe or prolonged, or acute medications are ineffective or overused.

Oral Medications

  • Beta-blockers: propranolol, metoprolol (first-line)
  • Antiepileptics: topiramate, valproate
  • Antidepressants: amitriptyline, venlafaxine
  • Candesartan, flunarizine

CGRP Monoclonal Antibodies

Erenumab (anti-CGRP receptor), fremanezumab, galcanezumab, and eptinezumab (anti-CGRP ligand) are monthly or quarterly subcutaneous/IV injections. They reduce monthly migraine days by 50% or more in about 50% of patients [5].

OnabotulinumtoxinA (Botox)

FDA-approved for chronic migraine (15+ headache days/month). 31 injection sites across the head and neck every 12 weeks.

Neuromodulation

  • Single-pulse TMS (sTMS): FDA-cleared for acute and preventive migraine treatment
  • Non-invasive vagus nerve stimulation (nVNS): gammaCore device for acute and preventive use
  • External trigeminal nerve stimulation (eTNS): Cefaly device for prevention

Medication Overuse Prevention

Limit acute medication use to no more than 2-3 days per week. Triptans: maximum 10 days/month. Simple analgesics: maximum 15 days/month. Keep a medication diary to track usage.

Lifestyle Management

  • Identify and avoid personal triggers (keep a headache diary)
  • Regular sleep schedule
  • Regular aerobic exercise (150 minutes/week)
  • Stress management techniques
  • Adequate hydration and regular meals

Frequently Asked Questions

FAQ content is being prepared.

References

  1. [1] Eigenbrodt AK, Ashina H, Khan S, Diber-Laskos S, Pritchard C, Gosalia H, Ashina M (2021). "Diagnosis and management of migraine in ten steps." Nature Reviews Neurology, 17: 501-514. DOI PubMed
  2. [2] Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018). "CGRP as the target of new migraine therapies — successful translation from bench to clinic." Nature Reviews Neurology, 14: 338-350. DOI PubMed
  3. [3] Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM (2019). "Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial." JAMA, 322: 1887-1898. DOI PubMed
  4. [4] Ailani J, Burch RC, Robbins MS (2021). "The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice." Headache, 61: 1021-1039. DOI PubMed
  5. [5] Tassorelli C, Greco R, Ferraris A, De Icco R (2020). "Non-invasive vagus nerve stimulation for the treatment of migraine." Expert Review of Neurotherapeutics, 20: 735-743. DOI PubMed
migraine treatmenttriptansCGRPpreventive therapyBotoxneuromodulation

This content is provided for medical informational purposes only and cannot replace professional medical advice. If you have symptoms, please consult a specialist.

Are you concerned about related symptoms?

Get an accurate diagnosis at OSANG Neurosurgery.